Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Average (2016 - 2025)

Historic Equity Average for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $456.3 million.

  • Ocular Therapeutix's Equity Average rose 3673.76% to $456.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $456.3 million, marking a year-over-year increase of 3673.76%. This contributed to the annual value of $484.8 million for FY2025, which is 13855.19% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Equity Average is $456.3 million, which was up 3673.76% from $282.1 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Equity Average ranged from a high of $456.3 million in Q4 2025 and a low of $5.5 million during Q3 2023
  • Its 5-year average for Equity Average is $166.3 million, with a median of $83.8 million in 2021.
  • As far as peak fluctuations go, Ocular Therapeutix's Equity Average surged by 1365919.54% in 2021, and later crashed by 9121.0% in 2023.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Equity Average stood at $87.7 million in 2021, then crashed by 53.46% to $40.8 million in 2022, then increased by 21.29% to $49.5 million in 2023, then skyrocketed by 574.22% to $333.7 million in 2024, then surged by 36.74% to $456.3 million in 2025.
  • Its Equity Average stands at $456.3 million for Q4 2025, versus $282.1 million for Q3 2025 and $285.9 million for Q2 2025.